Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD)
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 1
Abstract
[b][/b]The authors summarize and update the most recent knowledge in the field of prevalence, natural history and incidence of Non Alcoholic Fatty Liver Disease (NAFLD) and Non Alcoholic Steatohepatitis (NASH). These novel diseases, firstly recognized at the beginning of the second millennium, arose suddenly to the attention of the clinicians, because they are the hepatic expression of the so-called metabolic syndrome. Due to the epidemic burden of obesity, diabetes, and metabolic diseases, NAFLD and NASH will become soon probably the most common hepatic disease worldwide, and they surely will keep busy our future young hepatologists.
Authors and Affiliations
Stefano Bellentani, Mariano Marino
Keywords
Related Articles
- EP ID EP77837
- DOI -
- Views 115
- Downloads 0
Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans
Introduction. Adherence to hepatitis C (HCV) care was suboptimal in the interferon era among underserved African Americans (AA), but adherence data in the era of direct acting antivirals (DAA) is lacking in this populati...
Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren’s syndrome
Background/Aims: Patients with primary Sjögren’s syndrome may present liver involvement. Our goals were to establish the prevalence of abnormal hepatic biochemistries and clinical liver disease in patients with primary S...
Clinical Characteristics and Complications of Pediatric Liver Biopsy: A Single Centre Experience
Introduction. Percutaneous liver biopsy (LB) is the gold standard method for evaluation and management of patients with liver disease. The purpose of this study was to characterize pediatric patients undergoing LB at Bri...
Predictors and impacts of hospital readmissions following liver transplantation
While liver transplantation is the definitive therapy for end stage liver disease, it remains a major procedure, with many potential complications. Hospital readmissions after the initial hospitalization for liver trans...
Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial
Introduction. The burden of non-alcoholic steatohepatitis (NASH) is growing and current pharmacologic treatments are limited by side effects and inconsistent efficacy. Pilot studies suggest that pentoxifylline (PTX) can...